



## OVERVIEW

Trovagene is currently partnering with Memorial Sloan Kettering Cancer Center and MD Anderson on two clinical studies enrolling ECD patients to evaluate urine-based cell-free tumor DNA testing to diagnose BRAF mutations in this disease.

## CONTACT INFORMATION

Both clinical studies are currently enrolling patients. For more information about these studies please contact the individuals listed below.

### Memorial Sloan Kettering Cancer Center

Eli Diamond, MD, phone: 212-639-7576 e-mail: [diamone1@mskcc.org](mailto:diamone1@mskcc.org)

Omar Abdel-Wahab, MD, e-mail: [abdelwao@mskcc.org](mailto:abdelwao@mskcc.org)

David Hyman, MD, phone: 646-888-4544 e-mail: [hymand@mskcc.org](mailto:hymand@mskcc.org)

### MD Anderson Cancer Center

Filip Janku, MD, Ph.D, phone: (713) 563-2632 e-mail: [fjanku@mdanderson.org](mailto:fjanku@mdanderson.org)

For more information about Trovagene please contact:

Rachel Ferkel, Market Development Manager

Email: [rferkel@trovogene.com](mailto:rferkel@trovogene.com)

Phone: (310) 270-8248

## STUDIES

### **Detection of BRAF mutations in urine and plasma cell-free DNA: Application to the diagnosis and management of histiocytic disorder patients.**

**Study Objective:** To detect and quantitatively assess BRAF V600E mutations in tumor derived cell-free (cf) DNA to monitor response to RAF targeted therapy in a large series of histiocytosis patients.

**Principal Investigator:** Eli Diamond, MD, Memorial Sloan-Kettering, New York City, NY

**Contact Information:** Eli Diamond, MD, phone: 646-888-4544  
e-mail: [diamone1@mskcc.org](mailto:diamone1@mskcc.org)

### **Longitudinal monitoring of BRAF V600E mutation in urinary cell-free DNA of patients with metastatic cancers and Erdheim Chester Disease**

**Study Objective:** This open-label, multi-center study will assess the detection and monitoring of BRAF V600E mutational tumor load. The study is open to ECD patients with BRAF V600 mutation positive lesions.

**Principal Investigator:** Filip Janku, MD., Ph.D., MD Anderson Cancer Center, Houston, TX

**Contact Information:** Filip Janku, MD, Ph.D, phone: (713) 563-2632  
email: [fjanku@mdanderson.org](mailto:fjanku@mdanderson.org)

**Requested Patient Involvement:** ECD patients being treated at MD Anderson are encouraged to enroll by having their treating physician contact Dr. Janku.